-
Janux Therapeutics (JANX) PT Lowered to $150 at Cantor Fitzgerald
-
Janux Therapeutics (JANX) PT Lowered to $45 at H.C. Wainwright
-
Janux Therapeutics (JANX) PT Lowered to $49 at BofA Securities
-
Janux Therapeutics (JANX) PT Lowered to $38 at Stifel
-
After-hours movers: MongoDB, Instacart, Iris Energy, Credo Technology and more
-
Wolfe Research Starts Janux Therapeutics (JANX) at Peerperform
-
Janux Therapeutics (JANX) PT Lowered to $65 at Jones Trading
-
Janux Therapeutics, Inc. (JANX) Tops Q3 EPS by 23c
-
Why UBS says Q4 is eventful for SMID oncology stocks
-
Barclays Starts Janux Therapeutics (JANX) at Overweight
-
Truist Securities Starts Janux Therapeutics (JANX) at Buy
-
Stifel Resumes Janux Therapeutics (JANX) at Buy
-
Guggenheim Starts Janux Therapeutics (JANX) at Buy
-
Piper Sandler Starts Janux Therapeutics (JANX) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating on Janux Therapeutics (JANX)
-
Raymond James Starts Janux Therapeutics (JANX) at Outperform
-
Citizens JMP shares updates on cancer treatment stocks
-
Janux Therapeutics (JANX) PT Lowered to $89 at Leerink Partners
-
Janux Therapeutics, Inc. (JANX) Misses Q1 EPS by 1c
-
Janux Therapeutics (JANX) initiates expansion Phase 1b studies for JANX007
-
Cantor Fitzgerald Reiterates Overweight Rating on Janux Therapeutics (JANX)
-
Janux Therapeutics (JANX) Appoints Zachariah McIver as Chief Medical Officer
-
BTIG Reiterates Buy Rating on Janux Therapeutics (JANX)
-
Clear Street Starts Janux Therapeutics (JANX) at Buy
-
Janux Therapeutics (JANX) Prices 5.32M Share Offering at $63/sh
-
Janux Therapeutics (JANX) PT Raised to $62 at Scotiabank
-
Janux Therapeutics (JANX) Announces Proposed $300M Share Offering
-
Janux Therapeutics (JANX) PT Raised to $105 at Jones Trading
-
TD Cowen Reiterates Buy on Janux Therapeutics (JANX) as JANX007 'Far Exceeds High Expectations'
-
Janux Therapeutics (JANX) PT Raised to $115 at Stifel
-
William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'
-
Janux Therapeutics (JANX) PT Raised to $91 at Leerink Partners
-
Janux Therapeutics (JANX) PT Raised to $70 at H.C. Wainwright
-
Janux Therapeutics (JANX) PT Raised to $200 at Cantor Fitzgerald, 'Mic Drop - '007 HRPC Update Waaayyy Above Expectations'
-
Janux Therapeutics (JANX) call put ratio 1 call to 2.8 puts into data
-
Stifel Reiterates Buy Rating on Janux Therapeutics (JANX)
-
Janux Therapeutics (JANX) PT Raised to $100 at BTIG, 'The World Is Not Enough — 007 Strikes Again Exceeding The Street's Highest Expectations'
-
Vir Biotechnology (VIR) Trades Higher in Sympathy with Janux Therapeutics (JANX)
-
Janux Therapeutics (JANX) Surges 40% After Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
-
After-hours movers: Zscaler, Honeywell, Microchip Technology and more
-
Janux Therapeutics (JANX) Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
-
Leerink Partners Starts Janux Therapeutics (JANX) at Outperform
-
Janux Therapeutics, Inc. (JANX) Misses Q3 EPS by 18c
-
UBS Starts Janux Therapeutics (JANX) at Buy
-
Stifel Starts Janux Therapeutics (JANX) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Janux Therapeutics (JANX)
-
Janux Therapeutics (JANX) PT Lowered to $42 at Scotiabank
-
Janux Therapeutics, Inc. (JANX) Tops Q2 EPS by 20c
-
Janux Therapeutics (JANX) Announces Updates to Board of Directors

